Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
65°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
732.20
-13.49 (-1.81%)
Official Closing Price
Updated: 6:30 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
Next >
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
February 15, 2024
From
FN Media Group LLC
Via
GlobeNewswire
The S&P 500's 3 best 10-year performers are all in this industry
February 13, 2024
Given the critical role semiconductors play in the global economy, it’s no surprise that chipmakers have hauled in some serious profits over the past decade.
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Economy
US Equities
Eli Lilly and Company (NYSE: LLY) is a Leading Gainer in Monday Morning Trading
February 05, 2024
Via
Investor Brand Network
Eli Lilly and Company (NYSE: LLY) Records 52-Week High Tuesday Morning
January 16, 2024
Via
Investor Brand Network
MarketBeat Week in Review – 2/5 - 2/9
February 10, 2024
The markets continue to rise as investors come to grips with higher interest rates, but next week's inflation data may cool down the bullish momentum
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Eli Lilly's formula for success: Blending innovation with insight
February 07, 2024
Eli Lilly showcases its financial strength and strategic innovation through its Q4 2023 earnings and forward-looking growth initiatives.
Via
MarketBeat
Markets suddenly price Eli Lilly stock for a breakout on earnings
February 05, 2024
The healthcare sector could see a sudden inflow of investment dollars, and Eli Lilly quickly becomes a favorite name in the space as markets and analysts bid up
Via
MarketBeat
Topics
Bonds
Economy
Exposures
Debt Markets
Interest Rates
Eli Lilly and Company (NYSE: LLY) Records 52-Week High Wednesday Morning
January 31, 2024
Via
Investor Brand Network
Pfizer’s earnings growth trade at a deep discount, suddenly a buy
January 29, 2024
The healthcare sector is set to attract a new inflow of investment dollars, as seen in business activity and employment. Pfizer is the clear sector favorite
Via
MarketBeat
Topics
Economy
Exposures
Economy
5 top healthcare stocks for earnings growth in 2024
January 25, 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.
Via
MarketBeat
2 biotechs with promising weight-loss drugs coming
January 16, 2024
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co.
Via
MarketBeat
AstraZeneca: Rebound in 2024 with double-digit earnings growth
January 11, 2024
AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition
Via
MarketBeat
Exposures
COVID-19
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
January 10, 2024
Via
Investor Brand Network
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
January 10, 2024
EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END
Via
FinancialNewsMedia
Where will S&P 500 go after new bullish levels?
January 09, 2024
Major indexes look resilient despite 2024's rocky start, getting support at key moving averages. Upcoming earnings could be catalysts in either direction.
Via
MarketBeat
Topics
ETFs
Stocks
Exposures
US Equities
Can Simply Good Foods ride the GLP-1 weight loss trend in 2024?
January 09, 2024
Simply Good Foods may be ready to breakout as the GLP-1 medication weight-loss trend is driving up sales for its Atkins and Quest Nutrition branded products
Via
MarketBeat
Merck, the Dow's hottest stock, gets set to report Q4 financials
January 08, 2024
Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
HCA Healthcare Rallies: Weight-loss drugs really a big threat?
January 08, 2024
HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges.
Via
MarketBeat
Topics
ETFs
Weight Watchers gains from Oprah’s GLP-1 weight-loss
January 02, 2024
Oprah Winfrey revealed she has lost over 60 pounds and is on the path to reaching her weight goal of 167 lbs. She credits this to taking GLP-1 medication
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
LifeMD expands telehealth GLP-1weight-loss service with Medifast
December 19, 2023
LifeMD Inc. (NASDAQ: LFMD) is a direct-to-consumer (DTC) comprehensive virtual healthcare platform. The company offers per-visit and membership plan pricing
Via
MarketBeat
Can Altimmune's weight-loss drug be a game-changer?
December 14, 2023
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold
Via
MarketBeat
Exposures
Product Safety
Neuropsychiatric Disorders and Treatment Market Projected to Show Strong Growth: Astrazeneca, AviadoBio, Astellas Pharma
December 07, 2023
Get an extensive Neuropsychiatric Disorders And Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.
Via
SBWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Ozempic vs. Mounjaro:: Battle of the bulge
December 04, 2023
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usage
Via
MarketBeat
Exposures
Product Safety
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
December 04, 2023
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet.
Via
MarketBeat
Topics
Bonds
Exposures
Debt Markets
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
November 29, 2023
Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis.
Via
SBWire
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
November 29, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
These are the top sectors for blue chip growth in 2024
November 29, 2023
The sector results will be mixed in 2024 but the Health Care, Communications and Technology sectors (and some of their stocks) will post robust gains.
Via
MarketBeat
Topics
Economy
Intellectual Property
Exposures
COVID-19
Intellectual Property
Interest Rates
Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029
November 17, 2023
EQNX::TICKER_START (OTCPK:CNER),(NASDAQ:PODD),(NASDAQ:TNDM),(NYSE:LLY),(NYSE:ABT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Type 1 Diabetes Market Comprehensive Study Explores Huge Growth by Key Players DiaVacs, XOMA Corp., Biodel, Macrogenics
November 14, 2023
Type 1 Diabetes Market Growth
Via
SBWire
Exposures
COVID-19
MarketBeat Week in Review – 11/6 - 11/10
November 11, 2023
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.